glembatumumab vedotin (CDX-011) / Celldex  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
glembatumumab vedotin (CDX-011) / Celldex
ACTRN12617001621303: Novel Triple Combination Immunotherapy for Patients with Metastatic Melanoma

Withdrawn
1
18
 
Central Adelaide Local Health Network, Celldex Therapeutics, Inc
Unresectable Metastatic Melanoma, Metastatic Melanoma not responding to Anti-PD1 Therapy
 
 
NCT03473691: Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer

Withdrawn
1
0
NA
Glembatumumab Vedotin, CDX-011
University of Virginia, Celldex Therapeutics
Triple Negative Breast Cancer
05/18
05/18

Download Options